While androgen receptor (AR) pathway inhibitors prolong survival in castrate resistance prostate cancer (CRPC), resistance rapidly develops and is often associated with increased stressactivated molecular chaperones like clusterin (CLU) and continued AR signaling. Since adaptive pathways activated by treatment facilitate development of acquired resistance, co-targeting the stress response, activated by AR inhibition and mediated through CLU, may create conditional lethality and improve outcomes. Here we report that CLU is induced by AR antagonism and silencing using MDV3100 and antisense, respectively, to become highly expressed in castrateand MDV3100-resistant tumors and cell lines. CLU, as well as AKT and MAPK signalosomes, increase in response to MDV3100-induced stress. Mechanistically, this stress response is coordinated by a feed-forward loop involving p90rsk (RPS6KA)-mediated phospho-activation of YB-1 with subsequent induction of CLU. CLU inhibition repressed MDV3100-induced activation of AKT and MAPK pathways. In addition, when combined with MDV3100, CLU knockdown accelerated AR degradation and repressed AR transcriptional activity through mechanisms involving decreased YB-1 regulated expression of the AR co-chaperone, FKBP52.
Introduction
Prostate cancer is the second leading cause of cancer deaths among males in Western countries (1) . While early-stage disease is treated with curative surgery or radiotherapy, the mainstay of treatment for locally advanced, recurrent or metastatic prostate cancer is androgen deprivation therapy (ADT), which reduces serum testosterone to castrate levels and suppresses androgen receptor (AR) activity. Despite high initial response rates after ADT, progression to castrate resistant prostate cancer (CRPC) occurs within 3 years (2) (3) (4) . The AR is the principle driver of CRPC (5) , and is supported by ADT-activated growth factor signaling pathways (6) , survival genes (7) , and cytoprotective chaperone networks (8) . Docetaxel (9) was the first therapy to prolong survival in CRPC, stratifying the treatment landscape into pre-and postchemotherapy states. More recently, the CYP17 inhibitor abiraterone (10) and the AR antagonist MDV3100 (11) have prolonged survival and are rapidly changing the CRPC treatment landscape. Despite significant responses (11, 12) , these novel AR pathway inhibitors activate redundant survival pathways that adaptively drive treatment resistance and recurrent CRPC progression. Realization of the full potential of AR pathway inhibition will require characterization of these stress-activated survival responses, and rational combinatorial cotargeting strategies designed to abrogate them.
Molecular chaperones play central roles in stress responses by maintaining protein homeostasis and regulating pro-survival signaling and transcriptional networks. Clusterin (CLU), a stress-activated chaperone transcriptionally regulated by HSF1 (13) , YB-1 (14) and others (15), inhibits stress-induced apoptosis by suppressing protein aggregation (16) , p53-activating stress signals (17), and conformationally-altered Bax (17, 18) while enhancing AKT phosphorylation (19) and trans-activation of NF-κB and HSF-1 (13, 20) . CLU is expressed in many human cancers (21, 22) , including prostate, where it increases following castration to become highly expressed in CRPC (23). CLU over-expression confers treatment resistance (24) , while CLU inhibition potentiates activity of most anti-cancer therapies in many preclinical models (25) (26) (27) .
The CLU inhibitor, OGX-011 (custirsen, OncoGenex Pharmaceuticals), is currently in Phase III trials after a randomized phase II study in CRPC reported 7 month gain in overall survival and 50% reduced death rate (HR=0.50) when combined with docetaxel (28) .
Since CLU is induced by treatment stress, including castration (23, 24) , and functions as a key mediator of the stress response (13) , we hypothesized that co-targeting the AR and stress-Research.
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Materials and Methods

Prostate Cancer Cell Lines and Reagents
LNCaP and C4-2 cells were kindly provided by Dr. L.W.K. Chung (1992, MDACC, Houston Tx) and authenticated by whole-genome and whole-transcriptome sequencing on Illumina Genome Analyzer IIx in July-2009 . PC3 cells were purchased from ATCC and authenticated by ATCC's isoenzyme analysis. CRPC and MDV3100 resistant tumors and cell lines were generated (S1) and as previously described (29) . Cycloheximide and MG-132 were purchased from Calbiochem, R1881 from Perkin-Elmer, and MDV3100 from Haoyuan Chemexpress Co., Limited. Antibodies used are listed in supplementary Material and Methods.
CLU siRNA and Antisense
CLU and control siRNAs were purchased from Dharmacon Research, Inc., as previously described (13) . Second-generation CLU antisense (OGX-011) and scrambled (ScrB) oligodeoxynucleotides (ODN) with a 2′-O-(2-methoxy)ethyl modification were supplied by OncoGenex Pharmaceuticals, while AR antisense were supplied by Isis Pharmaceuticals; these are described in supplementary Material and Methods. Prostate cells were treated with CLU and YB-1 siRNA or oligonucleotides, using protocols described previously (13, 14) .
Western blotting analysis and immunoprecipitation
Total proteins were extracted using RIPA buffer and submitted to western blot as we described previously (30) . For immunoprecipitation, total proteins were pre-cleared with protein-G sepharose (Invitrogen Life Technologies), immuno-precipitated with 2μg anti-AR and western blotted as previously described (30) .
Quantitative Reverse Transcription-PCR
Total RNA was extracted from cultured cells after 48 hours of treatment using TRIzol reagent (Invitrogen Life Technologies, Inc.) as previously reported (13) . Primers (described in supplementary Material and Methods) were normalized to b-actin levels as an internal standard, and the comparative cycle threshold (Ct) method was used to calculated relative quantification of target mRNAs. Each assay was performed in triplicate.
Immunofluorescence
Research.
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48 hours post transfection cells were treated with 10uM MDV3100 ± 1 nM R1881 for 6 hours.
Immunofluorescence was performed as previously reported (30) . Photomicrographs were taken at 20X magnification using Zeiss Axioplan II fluorescence microscope, followed by analysis with imaging software (Northern Eclipse, Empix Imaging, Inc.).
AR transcription activity
LNCaP, CRPC-V16D and MR49C cells (Kuruma et al., 2012) were treated with OGX-011 or ScrB control, CLU siRNA or Ctr siRNA and then transfected with PSA-luciferase PSAluciferase reporter (-6,100 to +12) or Probasin luciferase reporter along with renilla plasmid as previously described (30) . All experiments were carried out in triplicate wells and repeated five times using different preparations of plasmids.
Cell proliferation and cell cycle assays.
LNCaP, MR49C and MR49F cells (S1) were transfected with CLU siRNA, OGX-011 or ScrB control, and then treated with MDV3100 or DMSO control 24h after transfection. After a time course exposure, cell growth was measured by crystal violet assay as previously described (30) . Detection and quantitation of apoptotic cell cycle population were analyzed by flowcytometry as previously described (30) . Each assay was done in triplicate three times.
Crystal violet assay was used to determine synergism of combination therapy. LNCaP cells were treated with 10 nM CLU or ScrB siRNA, or 500 nM OGX-011 or ScrB ODN, and one day later combined with indicated concentration of MDV3100 or DMSO for 48h. CalcuSyn® software was used to calculate the combination index (CI) at several effective doses (CI=1; additive effect, CI<1; synergy effect, CI>1; antagonistic effect).
Protein stability and degradation
To assess effect of combination treatment on AR protein stability, LNCaP cells treated with OGX-011 or ScrB for 48 h followed by RPMI+5% FBS plus 10 μmol/L cycloheximide and 10 μmol/L MDV3100 for 2 to 6 or 16 h and western blotted using AR and vinculin antibodies.
Animal treatment
Male athymic mice (Harlan Sprague-Dawley, Inc.) were injected s.c. with 1×10 6 LNCaP cells suspended in matrigel. When tumors reached 150mm 3 are castrated. Once tumors progressed to CRPC, mice were randomly assigned to 10mg/kg MDV3100 daily plus either 10 mg/kg OGX-011 or ScrB ODN i.p. once daily for 7 days and then three times per week thereafter. Each experimental group consisted of 12 mice. Tumor volume and serum PSA was measured as previously described (13) . All animal procedures were performed according to the guidelines of the Canadian Council on Animal Care.
Statistical analysis
All results are expressed as the average ± SE. Two-tailed t-tests, one-way ANOVA or 
Results
CLU is highly expressed in MDV3100 resistant xenografts and cell lines:
To understand mechanisms of MDV3100 recurrence, we developed LNCaP-derived MDV3100 resistant tumors and cell lines (Kuruma et al., 2013) (S1) and confirmed that CLU levels were increased by western blot (Fig 1A, left) and immunohistochemistry ( Fig. 1A middle and right panels). Elevated CLU was also observed in most MDV3100 resistant cell lines derived from these xenografts ( Fig. 1B) . These data indicate that CLU increases with MDV3100 resistance, similar to comparisons between castrate sensitive and CRPC tumors (24) .
AR pathway inhibition induces CLU:
We used MDV3100 and AR antisense approaches to assess effects of AR pathway inhibition on CLU induction in MDV3100-sensitive and -resistant LNCaP cells. Similar to bicalutamide and ADT using CSS (S2), MDV3100 induces CLU in both a time-and dose-dependent manner in castrate-sensitive LNCaP (Fig. 1C ) and castrate-resistant C4-2 (S3) cells, in parallel with reduced AR activity as indicated by decreased PSA expression. This data suggest that MDV3100 induces activation of CLU, similar to that seen with first line ADT in castrate-sensitive tumors (24) . To determine whether CLU is also induced as a consequence of AR inhibition even in MDV3100 resistant cells, AR-ASO targeting exon 1 and intron 1 of the AR were used. Both AR-ASO potently down-regulate AR in a dose-dependent and sequence-specific manner in MR49F cells, with parallel induction of CLU, (Fig. 1D ). These data suggest that AR pathway inhibition by ADT, AR antagonism, or antisense knockdown induces CLU in castrate-sensitive and -resistant cells, possibly as an early adaptive response to AR-inhibited stress.
MDV3100-induced CLU is mediated via p90Rsk-YB-1 signaling pathway:
We next set out to define transcriptional regulation of CLU induction following MDV3100 treatment stress. We recently reported that CLU is up-regulated via YB-1 after treatment stress (14) ; YB-1 is stress-activated via phosphorylation by AKT and p90RSK (a RPS6KA multigene family member) (31, 32), stimulating its nuclear translocation. While MDV3100 has been reported to activate AKT (33), we found that MDV3100 also induces a downstream effector of ERK, p90Rsk ( Fig. 2A Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 20, 2013; DOI: 10.1158/0008-5472.CAN- hypothesized that MDV3100 induces CLU up-regulation via phospho-activation of YB-1. Figure   2A confirms that MDV3100 increases downstream effectors of AKT (pS6K) and Erk (p90Rsk), accompanied by increased phospho-YB-1 levels. YB-1 silencing abrogates MDV3100-induced CLU expression at both the protein and mRNA levels ( Fig. 2B ), suggesting that MDV3100induced CLU is mediated by YB-1. Since YB-1 can be phospho-activated by both AKT and p90Rsk (31, 32), we next defined which pathway mediating MDV3100-induced up-regulation of CLU using inhibitors of AKT (LY294002) and p90Rsk (SL0101). MDV3100-induced upregulation of CLU was abrogated by p90Rsk ( Fig. 2C left 
CLU knockdown synergistically enhances MDV3100-induced inhibition of LNCaP cell growth:
Because AR pathway inhibition induces CLU ( Fig. 1 ), which has anti-apoptotic functions and a role in treatment resistance, we evaluated whether CLU knockdown potentiates the activity of MDV3100. LNCaP cells were treated with the CLU antisense drug, OGX-011, followed by 
Combined MDV3100 plus OGX-011 synergistically delays CRPC LNCaP tumor growth:
Author Manuscript Published OnlineFirst on June 20, 2013; DOI: 10.1158/0008-5472.CAN- We next evaluated the in vivo effects of co-targeting the AR and stress response using combined OGX-011 and MDV3100 in CRPC LNCaP model. Male nude mice bearing LNCaP xenografts were castrated when serum PSA reached 75ng/ml and followed until serum PSA and tumor growth rates increased back to pre-castrate levels, indicating progression to castration resistance. Mice were then randomly assigned for treatment with MDV3100 plus either control (n = 12) or OGX-011 (n=12). At baseline, mean LNCaP tumor volume and serum PSA levels were similar in both groups. OGX-011 significantly enhanced the antitumor effect of MDV3100, reducing mean tumor volume from 1600 mm 3 to 650 mm 3 by 12 weeks (**; 
Combination MDV3100 plus CLU silencing reduces AR nuclear translocation and transcriptional activity:
Analysis of in vivo studies suggest that combination MDV3100+OGX-011 led to PSA decreases disproportionate to changes in tumor volume compared to MDV3100 monotherapy tumors; we therefore explored effects of CLU inhibition on AR signaling under conditions of MDV3100 treatment. Castrate sensitive LNCaP and CRPC LNCaP-derived (V16D) cells were treated with MDV3100 +/-OGX-011 and evaluated for changes in R1881-stimulated PSA transactivation. As expected, MDV3100 reduced R1881-induced AR transcription as measured by PSA luciferase transactivation assay (Fig. 5A) ; interestingly, CLU siRNA also reduced AR activity and this effect was enhanced by MDV3100, suggesting that CLU knockdown potentiates MDV3100 inhibition of AR activity. Similar data were obtained using CLU siRNA in androgen independent AR+ LAPC4 and 22RV1 cells, CRPC and MDV3100-resistant LNCaP cells (S5). MDV3100
and CLU silencing also inhibited AR-regulated gene expression, which was maximally reduced by combination therapy (Fig. 5B ). In keeping with these observations, immunofluorescence ( 5C) and sub-cellular fractionation studies ( Fig. 5D ) confirm that MDV3100 inhibition of R1881induced AR nuclear translocation was significantly enhanced in combination with CLU siRNA.
CLU knockdown combined with MDV3100 accelerates proteasome-mediated AR degradation:
We found that CLU silencing decreases AR protein levels in parental LNCaP (Fig. 6A ), CRPC LNCaP-derived V16D (S6 left), and MDV-resistant LNCaP-derived cells (S6 right) as well as in LAPC4 and 22RV1 cells (S7); these changes are seen at the protein, but not mRNA, levels ( Fig.   6A lower panels) and enhanced by MDV3100, suggesting that CLU knockdown in combination with MDV3100 alters AR protein stability. The effect of CLU silencing -/+MDV3100 on AR biosynthesis using cycloheximide was next evaluated. Both MDV3100 and CLU siRNA induced rapid and profound decrease of AR 6 hours after cyclohexamide while this effect was seen after only 2 hours when MDV3100 was combined with CLU knockdown (Fig. 6B ). These data suggest that CLU silencing and MDV3100 both decrease AR protein turnover, but this effect is potentiated when combined.
Protein ubiquitination and acetylation are important determinants of AR transcriptional activation (35) (36) . AR forms a heterodimer complex with Hsp90 to provide stability for ligandunbound AR; without Hsp90 binding, the AR is ubiquitinated and degraded by the proteasome (37, 38) . We found that MDV3100 increases AR-Hsp90 heterocomplex levels (Fig. 6C ), consistent with prior reports that MDV3100 sequesters AR in the cytoplasm (11), with decreased AR acetylation ( Fig. 6C ) and AR transcriptional activity (Fig. 5A ). Interestingly, CLU knockdown profoundly decreases AR/Hsp90 heterocomplex and AR acetylation levels (Fig. 6C) .
These data are consistent with a view that the MDV3100-AR-Hsp90 heterocomplex becomes more vulnerable to degradation under conditions of CLU silencing. The proteasome inhibitor, MG132, abrogated AR degradation under conditions of CLU knockdown plus MDV3100 ( Fig   6D, left) with increased ubiquitinated AR levels (Fig. 6D, middle and right) . Collectively, these data suggest that when CLU knockdown is combined with MDV3100, the AR is deacetylated and ubiquitinated with accelerated proteasome-mediated degradation.
CLU knockdown decreases levels of the molecular co-chaperone FKBP52:
Author Manuscript Published OnlineFirst on June 20, 2013; DOI: 10.1158/0008-5472.CAN- The preceding data indicate that MDV3100-sequestered, AR-Hsp90 cytoplasmic heterocomplexes, when combined with CLU knockdown, are destabilized and lead to AR ubiquitination and degradation with reduced AR nuclear translocation and activity. One explanation is that CLU inhibition may lower Hsp90 levels through its regulation of HSF-1 activity (13); however, MDV3100 did not induce HSF-1 activity (S8), and combination therapy did not lower levels of the HSF-1 regulated gene, Hsp90 (Fig 6C, input) . These observations, along with data in Figure 2 , implicate YB-1, rather than HSF-1, as the key stress-activated transcription factor mediating MDV3100 increases of CLU. Since Hsp90 cooperates with other co-chaperones to stabilize client proteins, we initially used an unbiased approach to identify AR-Hsp90 co-chaperones regulated by CLU. Gene profiling analysis from LNCaP and PC-3 cells treated with control vs. CLU siRNA indicated that CLU expression correlated with the Hsp90 co-chaperone FKBP52 (Hsp56) and that CLU knockdown reduces FKBP52, but not FKBP51 or Hsp90, protein levels while abrogating MDV3100-induced phosphorylation of YB-1, pAKT, and p90Rsk ( Fig. 7A ). To define how FKBP52 levels decrease under conditions of MDV3100induced stress and CLU knockdown, we mined public databases and found that YB-1 binds to FKBP52 DNA with a high stringency of 12 in ChIP on ChIP analysis (39) . Western blotting confirmed that YB-1 knockdown decreases FKBP52 expression levels ( Fig 7B) . To ascertain the role of FKBP52 in AR stability under conditions of CLU silencing, FKBP52 was overexpressed after CLU knockdown and AR expression was evaluated. Figure 7C shows that FKBP52 partially rescues AR from degradation induced by CLU knockdown. FKBP52 overexpression also partially restores PSA expression, indicating increased AR activity when FKBP52 levels are restored under conditions of CLU knockdown. These data suggest that CLU regulates the stability of the AR-co-chaperone complex by affecting FKBP52 levels. While FKBP52 rescue can partially reverse CLU knockdown effects on AR stability in the absence of MDV3100, AR levels were not rescued when MDV3100 is present ( Fig 7C) . These data define an MDV3100induced feed-forward loop involving pYB-1, p90rsk, CLU, and the AR co-chaperone FKBP52 that collectively support AR stability, nuclear translocation and activation that may be cotargeted using OGX-011.
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Discussion
Many strategies used to kill cancer cells induce stress-and redundant survival responses that promote survival and emergence of treatment resistance, which is the underlying basis for most cancer deaths. This therapeutic resistance results from the Darwinian interplay of innate and adaptive survival pathways activated by selective pressures of treatment. In prostate cancer, castration induces apoptosis and clinical responses in most patients but also triggers progression to CRPC (2, 3) . Similarly, newer AR pathway inhibitors like abiraterone and MDV3100 prolong survival but resistance develops in many initial responders (11, 12, 40) . Disease progression frequently correlates with rising PSA levels, indicating continued AR signaling and highlighting need for additional therapies targeting the molecular basis of treatment resistant CRPC. Defining interactions between the AR and redundant survival pathways will build new combinatorial strategies that control progression and improve outcomes.
Persistent AR signaling in CRPC can occur via AR amplification or mutations, as well as altered levels of AR co-activators or co-chaperones (41) (42) (43) (44) . Another more dynamic mechanism involves reciprocal feedback regulation between AR and PI3K pathways whereby AR inhibition activates AKT signaling by reducing levels of the AKT phosphatase PHLPP, and PI3K inhibition activates AR signaling by relieving feedback inhibition of HER kinases; inhibition of one activates the other, thereby enhancing survival (33) . These insights guide design of combinatorial regimens co-targeting the AR pathway and AKT or Hsp chaperones Hsp90 and Hsp27 (45) .
Since AR pathway inhibition is known to induce stress and CLU with reciprocal pathway activation of AKT (34), targeting the stress response activated by AR pathway inhibitors is another combinatorial strategy. This study defines feed-forward links between stress-induced YB-1 to CLU activation in parallel with enhanced AKT and MAPK signaling which collectively support AR stability and activity during MDV3100 treatment. YB-1 and CLU are both stressactivated survival chaperones functionally associated with cancer treatment resistance (14) .
Under stress conditions, YB-1 is phospho-activated by AKT (31) and p90RSK (32), stimulating its nuclear translocation and binding to target promoters. Our findings identify p90RSK as the predominant pathway increasing CLU expression after MDV3100 treatment, while YB-1 knockdown abrogates MDV3100-induced CLU. We previously reported that YB-1 transcriptionally enhances CLU following treatment stress and CLU functions as a key mediator of paclitaxel resistance in prostate cancer (14) . Together, these data suggest that MDV3100induced CLU occurs via p90RSK and YB-1 signaling pathway.
This stress-activated anti-apoptotic function for CLU can lead to resistance to many anti-cancer therapies. The CLU antisense inhibitor, OGX-011, enhances cancer cell death in combination with therapeutic stressors in many preclinical cancer models (15). Phase III trials evaluating combined docetaxel plus OGX-011 are underway in men with metastatic CRPC after randomized Phase II studies reported a survival benefit when OGX-011 was added to docetaxel (15). While CLU inhibition can enhance castration and delay time to CRPC in castrate sensitive xenografts (24, 46) , MDV3100 now enables investigation of AR pathway and CLU inhibition in CRPC models. In this study, we show that CLU is induced by MDV3100 and AR knockdown in MDV-sensitive and -resistant LNCaP cells, respectively, and that CLU remained highly expressed in most MDV3100-resistant xenografts and cell lines. Mechanistically, MDV3100induced crosstalk activation of AKT and MAPK pathways was repressed when combined with OGX-011, and co-targeting AR and CLU synergistically enhanced apoptotic rates over monotherapy. Unexpectedly, we found that AR ubiquitination and proteasome-mediated degradation rates were accelerated when MDV3100 was combined with CLU knockdown.
Stress-activation of YB-1 and MAPK was blunted with combined therapy, resulting in decreased YB-1-regulated levels of FKBP52 (Hsp56), which led to AR ubiquitination, proteasomal degradation and decreased transcriptional activity beyond that observed with MDV3100 monotherapy.
These results highlight a role for CLU in supporting YB-1-mediated expression of other molecular chaperones under context-dependent stress conditions, analogous to CLU-enhanced HSF-1-mediated transactivation of Hsp70 and Hsp27 after Hsp90 inhibition (13) . HSF-1 and YB-1 orchestrate expression of other molecular chaperones involved in processes of folding, trafficking, and transcriptional activation of the AR. In the absence of ligand, AR is predominately cytoplasmic, maintained in an inactive, but highly responsive state by a large dynamic heterocomplex composed of Hsp90 and Hsp70, and co-chaperones like FKBP52.
These Hsp-AR co-chaperones support AR stability and activation (47, 48) . Compared to the first-generation AR antagonist bicalutamide, which leads to AR dissociation from its Hsp 
Disclosure of Potential Conflicts of Interest
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Figure legends
Figure 2: MDV3100-induced CLU is mediated via p90Rsk-YB-1 signaling pathway. A) MDV3100 activates AKT and MAPK pathways:
LNCaP cells were treated with 10 uM MDV3100 for indicated times and western blotted using CLU, p-Rsk/R/Rsk, p-S6K/S6K, and pYB-1/YB-1. Vinculin was used as a loading control. B) YB-1 knockdown decreases MDV3100induced CLU: LNCaP cells were transfected with YB-1 or control siRNA and treated with 10μM MDV3100 for indicated time. Proteins were extracted for western blot using YB-1 and CLU and actin as loading control (upper panel). Lower panel shows qRT-PCR using CLU-specific primers and GAPDH as internal control. C) MDV3100-induced CLU is mediated via p90Rsk-YB-1 signaling pathway: LNCaP cells were treated with MDV3100, Akt inhibitor (LY294002), or in combination for 24 hours. Proteins were extracted for western blot using CLU, pAkt/Akt, and pYB-1/YB-1 (left panel). LNCaP cells were treated with MDV3100, p90Rsk inhibitor (SL0101) or in combination for 24 hours. Proteins were extracted for western blots using indicated antibodies (right panel).
Figure 3: CLU knockdown synergistically enhances MDV3100 activity. A) CLU knockdown potentiates MDV3100-inhibited cell growth:
LNCaP cells were treated with 500 nmol/L OGX-011 or control ScrB, followed by MDV3100 for indicated times (left) or concentration (right). Cell growth was determined by crystal violet assay. B) CLU knockdown synergizes MDV3100 inhibition of cell growth: dose-dependent effects and CI values calculated by CalcuSyn software were assessed in LNCaP cells treated for 48 hours with OGX-011 or MDV3100 monotherapy or combination at indicated concentration with constant ratio design between both drugs. C) CLU enhances MDV3100-induced apoptosis: LNCaP cells were treated with 500 nmol/L OGX-011 or control followed by 10 uM MDV3100 for 48 hours and the proportion of sub-G 1 , G 0 -G 1 , S, and G 2 -M cells determined by propidium iodide staining (left panel). Proteins were extracted for western blot using cleaved PARP, cleaved caspase-3, and CLU. Vinculin was used as a loading control (right panel). 
Figure 6: CLU knockdown combined with MDV3100 accelerates AR proteasomal degradation. A) CLU knockdown in combination with MDV3100 decreases AR protein levels:
LNCaP cells were treated with either OGX-011 (left panel) or CLU siRNA (right panel) and treated -/+10uM MDV3100 for 24hrs and western blot was performed for AR and CLU (upper panels). Vinculin was used as a loading control. qRT-PCR (lower panels) was used to evaluate expression of AR. B) CLU plus MDV3100 alters AR stability: LNCaP cells were treated with OGX-011 or SCRB -/+ MDV3100 followed by 10μmol/L cycloheximide treatment. Proteins were extracted and western blot performed for AR. C) CLU knockdown reduces MDV3100induced AR/Hsp90 heterocomplex levels: LNCaP cells were treated with CLU or control siRNA +/-10uM MDV3100. Total proteins were extracted, AR immunoprecipitated, and western blot performed using Hsp90 and Acy-Lys-AR to measure AR acetylation. D) CLU knockdown combined with MDV3100 induces AR ubiquitination and proteasomal degradation: LNCaP cells were treated with CLU or control siRNA with 10 μM MDV3100 for 24 hours and then +/-MG-132 for 6 hours. Proteins were extracted for western blot using AR (left panel). LNCaP cells were treated with CLU or control siRNA +/-10μM MDV3100 for 24 hours and then MG-132 for 6 hours. Proteins were immunoprecipitated using AR and western blot performed using AR (middle panel). LNCaP cells were transfected with His ubiquitin and AR and followed by siRNA CLU or control siRNA treatment +/-10μM MDV3100 for 24 hours and then MG-132 for 6 hours. Proteins were immunoprecipitated using ubiquitin and western blot performed using AR, ubiquitin antibodies (right panel). Proteins were extracted for western blot using indicated antibodies with actin used as loading control. B) YB-1 knockdown decreases FKBP52 expression: LNCaP cells were transfected with YB-1 or control siRNA and treated with 10μM MDV3100 for indicated times. Proteins were extracted for western blot using indicated antibodies. C) FKBP52 partially rescues AR degradation after CLU knockdown: LNCaP cells were transfected with FKBP52 Flag tagged construct or empty vector followed by CLU knockdown. 48 hours post-transfection, cells were treated with 10uM MDV3100 or vehicle for 24hours. Proteins were extracted for western blot using indicated antibodies. 
